Dear Editor, Randomised controlled trials (RCTs) provide the highest quality evidence for clinical practice. The broader applicability of RCT findings assumes that the study participants are representative of the population. However, systematic differences between study participants and nonparticipants may occur, in part due to stringent inclusion criteria. Recruitment into RCTs can also sometimes be difficult with many clinical trials reporting low recruitment rates for various reasons [1] . The aim of the present study was to compare the characteristics of eligible men with prostate cancer who did or did not consent to enrol in the ENGAGE study, a cluster randomised RCT to determine the impact of a clinician-referred exercise programme [2] .
The ENGAGE trial methodology and results have been reported in detail elsewhere [2] . In brief, patients who had undergone curative treatment for prostate cancer within the preceding 3-12 months at one of three major public hospitals and four private clinics located across metropolitan Melbourne were recruited through outpatients' clinics between October 2011 and June 2013. Patients who were non-English speaking or who had a known musculoskeletal, cardiovascular or neurological disorder were excluded. Consenting patients were referred to a defined exercise programme or standard care with subsequent assessment of exercise participation, quality of life, depression, and anxiety. The study received ethics approval from relevant Human Research Ethics Committees.
For the present analysis, de-identified data were collected from the screening logs on all patients who were eligible for the ENGAGE trial, including patient demographics, (sex, date of birth, and postcode of residence), treatment characteristics, (public vs private health service and modality of treatment), as well as disease characteristics (clinical stage, biopsy grade, and pretreatment serum levels of the tumour marker PSA). As a surrogate measure of the socio-economic status of patients, the Socio-Economic Indices for Areas (SEIFA) was used with higher SEIFA scores representing higher socioeconomic status [3] .
In all, 147 (45.9%) of 320 eligible patients agreed to participate in the trial; the patients' characteristics are summarised in Table 1 . Participants had a median (interquartile range [IQR]) age of 66 (61-73) years, slightly younger than non-participants with a median (IQR) age of 68 (63-73) years, although the difference was not statistically significant (P = 0.098). Trial participants also had higher SEIFA scores, with a median (IQR) SEIFA score of 1050 (1016-1076) compared to 1024 (982-1062) for nonparticipants (P < 0.001).
Compared to participants, non-participants in the trial were more likely to have been treated at a public health service (73.5% vs 84.4%, P < 0.03), to have undergone radiotherapy (49.0% vs 60.7%, P < 0.05) or to be treated with androgendeprivation therapy (28.0% vs 52.4%, P < 0.003). There were no marked differences in PSA level at diagnosis, clinical stage or biopsy Gleason score between patients who enrolled and those who did not.
In the present study, we found important demographic differences between participants and non-participants in this trial, which may have implications for the generalisability of study findings, as well as trial design. We found that less than half of the eligible patients participated in the trial, although this is a higher rate of participation compared to similar trials that report recruitment rates of 20-30% [4] . Patient factors known to impact recruitment into RCTs include: competing demands, anxiety around randomisation, and lack of understanding of complex information. Clinician factors impacting recruitment include: lack of resources, concerns over loss of autonomy, and lack of interest in the study question [5] .
We found that participants in the trial were on average in a more socially advantaged position, as evidenced by higher area-level socio-economic status (SEIFA) and more frequent treatment in private clinics than non-participants, although with marked overlap in distribution. This is, however, consistent with other studies, which show underrepresentation in RCTs by patients with lower socioeconomic status [1] . This may also reflect the nature of this trial, an exercise programme. Evidence supports that, in population studies, adults living in areas with the highest levels of disadvantage were less likely than those living in areas of least disadvantage to meet the recommended physical activity guidelines (27% compared with 38%). Other factors that may also impact on participation, such as ethnicity or co-morbidities, unfortunately could not be assessed in the present study.
Given the marked differences in demographic and treatment characteristics, we also expected to see some differences in terms of cancer characteristics, but none were seen. The pretreatment PSA level was slightly lower amongst participants, but this difference was not statistically significant. Stage and grade distributions were similar regardless of trial participation.
The findings from the present study contribute to the body of evidence that patients included in RCTs may not be entirely representative of the general population [6] . Given the voluntary nature of trial participation, some of this is inevitable, and a reflection of the patient's interest and ability to commit to the trial, and altruism. It is important to optimise trial design to overcome some of the known barriers to trial participation as outlined above [5] . Clinical practice is guided by findings from RCTs, but our present findings show that care needs to be taken in this extrapolation -thorough and transparent reporting of recruitment details for RCTs can facilitate this process.
